Proton therapy may prolong OS in stage II, III NSCLC

A study presented at this week’s ASCO (American Society of Clinical Oncology) Annual Meeting compared the OS (Overall Survival) rates for stage II/III non-small cell lung cancer using both photon and proton therapy treatments.

The study used 2004-2012 data from the National Cancer Database to retrospectively assess the outcomes of thoracic radiation in nearly 150,000 cases. Madhusmita Behera, PhD, director of Winship Research at Winship Cancer Institute at Emory University, concluded that “thoracic radiation with protons is associated with better survival rates in stage II/III NSCLC pts in this retrospective database analysis.”

Read the Healio coverage explaining the article here.

A link to the full journal article here.